0817 Unity
BioCentury & Getty Images

Product Development

Unity outlines path forward for anti-aging programs after Phase II osteoarthritis failure

UBX0101’s Phase II miss shaves $431M off the biotech’s market cap

Following a clinical failure in osteoarthritis, Unity is relying on more objective clinical endpoints and robust preclinical data for its next-in-line ophthalmology program.

Aug 18, 2020 | 1:13 AM GMT

After the failure of its lead anti-aging program in osteoarthritis, Unity believes more objective clinical endpoints and robust preclinical data for its next-in-line ophthalmology candidate mean

Read the full 827 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE